好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

2025 Annual Meeting | Industry Therapeutic Update from Immunovant, Inc.: Myasthenia Gravis – Evolving Therapeutic Landscape

Monday 04/07/25
06:00 PM - 08:00 PM PDT Add To Calendar
Marriott Marquis | San Diego B
This program will be presented in-person only
This program is not expected to be available in the meeting's On Demand product.
Industry Therapeutic Update
Richard J. Nowak, MD, Mamatha Pasnoor, MD, FAAN, Srikanth Muppidi, MD, FAAN
General Neurology, Autoimmune Neurology, Neuromuscular and Clinical Neurophysiology (EMG)
The program will review pathophysiology of myasthenia gravis (MG), with a focus on biologic mechanisms that are targeted by existing therapies. An expert panel will examine the contemporary approach to treatment, including current guidance for management of MG and the increasing role of new targeted therapies such as FcRn inhibitors and complement inhibitors. Finally, the outstanding unmet treatment needs and the potential of emerging treatments to close remaining treatment gaps will be discussed.
This program is NOT accredited for continuing education by any organization. Additionally, Industry Therapeutic Updates program content and the views expressed herein are those of the presenting corporate entity and not of the AAN. These programs are not an official part of the 2025 AAN Annual Meeting education or scientific programs, nor are they endorsed by the AAN. The AAN cannot affirm claims pertaining to FDA off-label medication, research use of pre-FDA drugs, or other research information that might be discussed. Industry Therapeutic Updates are industry events.
No CME available

Program Materials Program Evaluations

Event Timeline
06:00 PM - 08:00 PM PDT Speaker Industry Therapeutic Update from Immunovant, Inc.: Myasthenia Gravis – Evolving Therapeutic Landscape
Faculty Disclosures
Richard J. Nowak, MD Dr. Nowak has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion . Dr. Nowak has received personal compensation in the range of $500-$4,999 for serving as a Consultant for argenx. Dr. Nowak has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB. Dr. Nowak has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Immunovant . Dr. Nowak has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Cabaletta Bio . Dr. Nowak has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Amgen. Dr. Nowak has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Cour Pharma. Dr. Nowak has received personal compensation in the range of $500-$4,999 for serving as a Consultant for EMD Serono. Dr. Nowak has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Janseen . The institution of Dr. Nowak has received research support from UCB. The institution of Dr. Nowak has received research support from Alexion . The institution of Dr. Nowak has received research support from Janseen. The institution of Dr. Nowak has received research support from Immunovant . The institution of Dr. Nowak has received research support from argenx. The institution of Dr. Nowak has received research support from Amgen. Dr. Nowak has a non-compensated relationship as a Member of the Board of Directors with Myasthenia Gravis Foundation of America (MGFA) that is relevant to AAN interests or activities.
Mamatha Pasnoor, MD, FAAN Dr. Pasnoor has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Argenx BVBA. Dr. Pasnoor has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Janssen Pharmaceutical. Dr. Pasnoor has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Immunovant. Dr. Pasnoor has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB. Dr. Pasnoor has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Annexon. Dr. Pasnoor has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Grifols. Dr. Pasnoor has received personal compensation in the range of $500-$4,999 for serving as a Consultant for amgen.
Srikanth Muppidi, MD, FAAN Dr. muppidi has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Alexion. Dr. muppidi has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for argenx. Dr. muppidi has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB/Ra Pharma. Dr. muppidi has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Horizont Pharma. Dr. muppidi has received publishing royalties from a publication relating to health care.